Lapatinib for the treatment of HER2-overexpressing breast cancer.

Health technology assessment (Winchester, England)

Volumn 13 Suppl 3, Issue , 2009, Pages 1-6

  Jones, J ^a   Takeda, A ^b   Picot, J ^b   von Keyserlingk, C ^b   Clegg, A ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; DEOXYCYTIDINE; DRUG DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; FLUOROURACIL; LAPATINIB; QUINAZOLINE DERIVATIVE;

BIOSYNTHESIS; BREAST TUMOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYMOLOGY; FEMALE; HUMAN; METASTASIS; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; QUINAZOLINES; RECEPTOR, ERBB-2;

EID: 84886943115     PISSN: None     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta13suppl3/01     Document Type: Review

References (15)